Derniers essais


EudraCT Number: 2022-003594-33 Sponsor Protocol Number: EORTC-1984-BCG Start Date: 2023-06-16
Sponsor Name: European Organisation for Research and Treatment of Cancer (EORTC)
Full Title: Neoadjuvant Olaparib and Durvalumab for patients with BRCA-associated TripLE Negative Breast Cancer (NOBLE)
Medical condition: Triple negative breast cancer
Disease: Version SOC Term Classification Code Term Level
20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10075566 Triple negative breast cancer PT
Population Age: Adults, Elderly Gender: Male, Female
Trial protocol: FR (Ongoing) ES (Ongoing)
Trial results: (No results available)

EudraCT Number: 2022-002234-14 Sponsor Protocol Number: OR2805-101 Start Date: 2023-06-07
Sponsor Name: OncoResponse, Inc.
Full Title: A Phase 1-2 Study of OR2805 Alone and in Combination with other Anti-cancer Agents in Subjects with Advanced Malignancies
Medical condition: Solid tumor cancer
Disease: Version SOC Term Classification Code Term Level
Population Age: Adults, Elderly Gender: Male, Female
Trial protocol: ES (Ongoing) FR (Completed)
Trial results: (No results available)
EudraCT Number: 2022-003467-21 Sponsor Protocol Number: AROMUC5AC-1001 Start Date: 2023-06-07
Sponsor Name: Arrowhead Pharmaceuticals, Inc.
Full Title: A Phase 1/2a Study Evaluating the Effects of ARO-MUC5AC Inhalation Solution in Healthy Subjects and Patients with Asthma
Medical condition: Asthma
Disease: Version SOC Term Classification Code Term Level
20.0 10038738 - Respiratory, thoracic and mediastinal disorders 10003553 Asthma PT
Population Age: Adults Gender: Male, Female
Trial protocol: ES (Ongoing) PL (Ongoing)
Trial results: (No results available)

EudraCT Number: 2021-001403-33 Sponsor Protocol Number: TCTLR-101 Start Date: 2023-06-06
Sponsor Name: Ascendis Pharma Oncology Division A/S
Full Title: Phase 1/2, Open-label, Dose Escalation and Dose Expansion Study of TransCon TLR7/8 Agonist Alone or in Combination with Pembrolizumab in Participants with Locally Advanced or Metastatic Solid Tumor...
Medical condition: Locally advanced or metastatic solid tumor malignancies
Disease: Version SOC Term Classification Code Term Level
21.0 100000004864 10049280 Solid tumour LLT
21.1 100000004864 10065143 Malignant solid tumour LLT
21.1 100000004864 10065147 Malignant solid tumor LLT
21.1 100000004864 10065252 Solid tumor LLT
Population Age: Adults, Elderly Gender: Male, Female
Trial protocol: ES (Ongoing) HU (Prematurely Ended) NL (Ongoing) PL (Prematurely Ended)
Trial results: (No results available)
EudraCT Number: 2022-000690-73 Sponsor Protocol Number: BAY86-5321/21912 Start Date: 2023-06-06
Sponsor Name: Bayer AG
Full Title: A Parallel-group Phase 4, Open-label, Two-arm Study to Assess the Safety and Efficacy of Intravitreal (IVT) Aflibercept with Proactive customized Treatment Intervals in Patients ≥50 Years of Age wi...
Medical condition: Neovascular (wet) age-related macular degeneration
Disease: Version SOC Term Classification Code Term Level
20.0 10015919 - Eye disorders 10071129 Neovascular age-related macular degeneration PT
Population Age: Adults, Elderly Gender: Male, Female
Trial protocol: DE (Prematurely Ended) ES (Ongoing)
Trial results: (No results available)

EudraCT Number: 2022-000054-28 Sponsor Protocol Number: OLIGOTREAT Start Date: 2023-06-02
Sponsor Name: Klinikum der Universität München
Full Title: Combining Clemastine and Aerobic Exercise to Treat Cognitive Dysfunction in Schizophrenia by Targeting Myelin Plasticity (OligoTreat)
Medical condition: Schizophrenia
Disease: Version SOC Term Classification Code Term Level
20.0 10037175 - Psychiatric disorders 10039626 Schizophrenia PT
Population Age: Adults, Elderly Gender: Male, Female
Trial protocol: DE (Ongoing)
Trial results: (No results available)
EudraCT Number: 2021-003474-31 Sponsor Protocol Number: COAV101B12301 Start Date: 2023-06-01
Sponsor Name: Novartis Pharma AG
Full Title: A randomized, sham-controlled, double-blind study to evaluate the efficacy and safety of intrathecal (IT) OAV101 in patients with later onset Type 2 spinal muscular atrophy (SMA) who are ≥ 2 to
Medical condition: Spinal Muscular Atrophy
Disease: Version SOC Term Classification Code Term Level
20.1 10010331 - Congenital, familial and genetic disorders 10041582 Spinal muscular atrophy PT
Population Age: Children, Adolescents, Under 18 Gender: Male, Female
Trial protocol: DK (Ongoing) GR (Ongoing)
Trial results: (No results available)

EudraCT Number: 2022-002292-11 Sponsor Protocol Number: VX20-880-101 Start Date: 2023-06-01
Sponsor Name: Vertex Pharmaceuticals Incorporated
Full Title: A Phase 1/2 Study to Evaluate the Safety, Tolerability, and Efficacy of VX-880 in Subjects Who Have Type 1 Diabetes Mellitus With Impaired Hypoglycemic Awareness and Severe Hypoglycemia
Medical condition: Type 1 Diabetes Mellitus with Impaired Hypoglycemic Awareness and Severe Hypoglycemia
Disease: Version SOC Term Classification Code Term Level
20.0 10027433 - Metabolism and nutrition disorders 10012601 Diabetes mellitus PT
21.1 10027433 - Metabolism and nutrition disorders 10081605 Severe hypoglycemia LLT
Population Age: Adults, Elderly Gender: Male, Female
Trial protocol: DE (Temporarily Halted) NO (Temporarily Halted) NL (Ongoing) IT (Ongoing)
Trial results: (No results available)
EudraCT Number: 2022-002679-12 Sponsor Protocol Number: EOCRC1-22 Start Date: 2023-06-01
Sponsor Name: Enterome SA
Full Title: A phase 2 trial of EO2040, a miCrobiaL-derived peptide therApeUtic vaccine, in combination with nivolumab, for treatment of patients with circulating tumor DNA-dEfined minimal residual disease of c...
Medical condition: Patients with circulating tumor DNA-defined minimal residual disease of colorectal cancer stage II, III, or IV after completion of curative therapy .
Disease: Version SOC Term Classification Code Term Level
21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061451 Colorectal cancer PT
21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10010033 Colorectal cancer stage II PT
21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10010034 Colorectal cancer stage III PT
21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10010035 Colorectal cancer stage IV PT
Population Age: Adults, Elderly Gender: Male, Female
Trial protocol: DE (Completed) ES (Ongoing)
Trial results: (No results available)

EudraCT Number: 2022-003792-41 Sponsor Protocol Number: DAROTAXEL Start Date: 2023-05-26
Sponsor Name: Erasmus MC
Full Title: A randomized phase II trial of docetaxel or cabazitaxel with or without darolutamide in men with metastatic castration-resistant prostate cancer.
Medical condition: metastatic castration-resistant prostate cancer
Disease: Version SOC Term Classification Code Term Level
Population Age: Adults, Elderly Gender: Male
Trial protocol: NL (Ongoing)
Trial results: (No results available)